# CD155 (PVR)

Source: https://onco.cc/targets/pvr/  
OnCo record `pvr` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CD155 is the molecule on tumour cells that TIGIT and CD96 read; normal tissue barely shows it, many tumours show a lot. Every TIGIT antibody works by breaking the CD155 handshake.

## Summary

PVR (chromosome 19q13.31) encodes CD155, which mediates NK-cell adhesion and triggers NK effector functions through two NK-cell receptors, CD96 and CD226, at the immunological synapse (UniProt P15151). It is barely or weakly expressed in various normal human tissues but frequently over-expressed in malignant tumours, promotes invasion and migration, is associated with poor prognosis, and as the ligand of the co-stimulatory receptor CD226 and the co-inhibitory receptors TIGIT and CD96 it plays a dual role in onco-immunity (Kučan Brlić et al. 2017, Cell Mol Immunol).

## Fields

- Kind: Target
- Last checked: 2026-09-24
- Also known as: CD155; poliovirus receptor; Necl-5; NECL5; PVS
- Tags: checkpoint-map
- Symbol: PVR
- Class: checkpoint
- Biology: A nectin-like adhesion molecule and the poliovirus receptor; the shared ligand of the DNAM-1/TIGIT/CD96 axis.
- Where found: Weak in normal tissue, frequently over-expressed in malignant tumours (Kučan Brlić et al. 2017)

## Notes

- Prevalence not recorded: HGNC and UniProt carry no positivity rates.

## Sources

- HGNC HGNC:9705: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9705
- UniProt P15151: https://www.uniprot.org/uniprotkb/P15151/entry
- NCBI Gene 5817: https://www.ncbi.nlm.nih.gov/gene/5817
- Kučan Brlić et al. 2017, Cell Mol Immunol (Europe PMC): https://europepmc.org/article/MED/28730595

## Connected records

- targets: [CD112 (nectin-2)](https://onco.cc/targets/nectin2/), [CD96](https://onco.cc/targets/cd96/), [TIGIT](https://onco.cc/targets/tigit/)
- drugs: [Tiragolumab](https://onco.cc/drugs/tiragolumab/)
- technologies: [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/)
- pathways: [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)
- terms: [Checkpoint (two meanings)](https://onco.cc/terms/checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/pvr.json